Related Experiment Video
Updated: Feb 23, 2026

X-Ray Crystallography to Study the Oligomeric State Transition of the Thermotoga maritima M42 Aminopeptidase TmPep1050
Published on: May 13, 2020
Dissecting the structure-function relationship in lysozyme domain of mycobacteriophage D29-encoded peptidoglycan
Himanshu Joshi1, Surya P Seniya1, Venkatesan Suryanarayanan2
1Microbiology and Molecular Biology Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research (IISER), Bhopal, India.
Abstract:
Most bacteriophages rapidly infect and kill bacteria and, therefore, qualify as the next generation therapeutics for rapidly emerging drug-resistant bacteria such as Mycobacterium tuberculosis. We have previously characterized the mycobacteriophage D29-generated endolysin, Lysin A, for its activity against mycobacteria. Here, we present a detailed characterization of the lysozyme domain (LD) of D29 Lysin A that hydrolyzes peptidoglycan of both gram-positive and gram-negative bacteria with high potency. By characterizing an exhaustive LD protein variant library, we have identified critical residues important for LD activity and stability. We further complement our in vitro experiments with detailed in silico investigations. We present LD as a potent candidate for developing phage-based broad-spectrum therapeutics.
Insights
Mycobacteriophage D29 Lysin A’s lysozyme domain (LD) effectively breaks down bacterial peptidoglycan. This research identifies key residues for enhanced LD activity, supporting its potential as a broad-spectrum therapeutic agent.
Area of Science:
- Microbiology
- Biochemistry
- Structural Biology
Background:
- Bacteriophages offer a promising avenue for combating drug-resistant bacteria, including Mycobacterium tuberculosis.
- Mycobacteriophage D29 Lysin A has demonstrated antimycobacterial activity.
- The lysozyme domain (LD) of Lysin A is a key component responsible for hydrolyzing bacterial cell walls.
Discussion:
- This study details the characterization of the D29 Lysin A lysozyme domain (LD).
- The LD exhibits potent peptidoglycan hydrolysis against both gram-positive and gram-negative bacteria.
- Identification of critical residues influencing LD activity and stability was achieved through extensive variant library analysis.
Key Insights:
- The lysozyme domain (LD) of D29 Lysin A is a potent enzyme capable of degrading peptidoglycan in a broad range of bacteria.
- Specific amino acid residues crucial for the LD's enzymatic activity and structural integrity have been identified.
- In silico methods were employed to complement in vitro findings, providing a comprehensive understanding of LD function.
Outlook:
- The characterized LD presents a strong candidate for the development of novel, phage-based, broad-spectrum antibacterial therapeutics.
- Further research could focus on optimizing LD variants for enhanced efficacy and stability in therapeutic applications.
- The findings contribute to the growing field of phage-derived antimicrobials as an alternative to conventional antibiotics.
More Related Videos
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
07:08Optimization of Synthetic Proteins: Identification of Interpositional Dependencies Indicating Structurally and/or Functionally Linked Residues
Published on: July 14, 2015
Related Concept Videos
Lysosomal Hydrolases
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Peptidoglycan Synthesis
Formation of Lipopolysaccharides
Protein Folding
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...